Open-Angle Glaucoma (OAG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Open-Angle Glaucoma (OAG) Market Outlook

Thelansis’s “Open-Angle Glaucoma (OAG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Open-angle glaucoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Open-Angle Glaucoma (OAG) Overview

Open-angle glaucoma is a progressive optic neuropathy characterized by the acquired loss of retinal ganglion cells and atrophy of the optic nerve. It constitutes over 90 percent of glaucoma cases in the United States. Elevated intraocular pressure stands as a major risk factor, though it is not a diagnostic criterion. Patients with elevated intraocular pressure have an approximately 1 percent per year risk of developing glaucomatous optic nerve damage. The pathophysiology involves a progressive reduction in the number of retinal ganglion cells, resulting from the pinching and death of nerve fibers at the point where the optic nerve exits the eye. This process leads to thinning of the neural rim and progressive enlargement of the optic nerve cup, causing a permanently decreased visual field. The only known causative risk factors for open-angle glaucoma are elevated intraocular pressure and insults to the eye, including uveitis, trauma, and steroid therapy. Although steroid therapy may contribute to elevated intraocular pressure, topical eye, and periocular steroids are most likely to increase pressure. Associated risk factors, in addition to age, include black race, which increases the prevalence of glaucoma fourfold, and a positive first-degree family history, which increases the prevalence sevenfold. Patients with glaucoma rarely exhibit symptoms, and it is often incidentally discovered during adult eye evaluations performed for other reasons. Initial treatment for open-angle glaucoma typically involves eye drops, which reduce intraocular pressure by decreasing aqueous production or increasing aqueous outflow. The choice between medical, surgical, or laser treatment as the optimal first-line therapy depends on individual patient considerations.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: